• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗胆碱能药物诱发的舞蹈症在局限性肌张力障碍治疗中的应用

Anticholinergic-induced chorea in the treatment of focal dystonia.

作者信息

Nomoto M, Thompson P D, Sheehy M P, Quinn N P, Marsden C D

机构信息

University Department of Neurology, Institute of Psychiatry, Denmark Hill, London, England.

出版信息

Mov Disord. 1987;2(1):53-6. doi: 10.1002/mds.870020107.

DOI:10.1002/mds.870020107
PMID:3504259
Abstract

The occurrence of chorea, induced by trihexyphenidyl (benzhexol hydrochloride) during the treatment of five adult patients who had focal or segmental dystonia, is described. The dose at which chorea appeared ranged from 15 to 60 mg/day (mean 31.7 mg/day). All but one patient had developed common adverse effects of this drug (dry mouth, blurred vision, and confusion) at lower doses (mean 21.8 mg per day). There was an inverse relationship between the age of the patient and the dose of trihexyphenidyl at which chorea developed.

摘要

本文描述了在治疗5例患有局灶性或节段性肌张力障碍的成年患者时,由苯海索(盐酸苯海索)诱发的舞蹈症的发生情况。出现舞蹈症的剂量范围为15至60毫克/天(平均31.7毫克/天)。除1例患者外,所有患者在较低剂量(平均每天21.8毫克)时均出现了该药物的常见不良反应(口干、视力模糊和意识模糊)。患者年龄与出现舞蹈症时苯海索的剂量之间存在反比关系。

相似文献

1
Anticholinergic-induced chorea in the treatment of focal dystonia.抗胆碱能药物诱发的舞蹈症在局限性肌张力障碍治疗中的应用
Mov Disord. 1987;2(1):53-6. doi: 10.1002/mds.870020107.
2
Choreiform movements induced by anticholinergic therapy.抗胆碱能疗法诱发的舞蹈样动作。
Med J Aust. 1979 May 19;1(10):465.
3
Persistent chorea in DYT6, due to anticholinergic therapy.
Parkinsonism Relat Disord. 2015 Oct;21(10):1282-3. doi: 10.1016/j.parkreldis.2015.07.024. Epub 2015 Aug 5.
4
Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients.短期和长期给予张力障碍患者苯海索后的药代动力学。
Ann Neurol. 1985 Jul;18(1):35-40. doi: 10.1002/ana.410180107.
5
Life-threatening cranial dystonia following trihexyphenidyl withdrawal.停用苯海索后出现危及生命的颅肌张力障碍。
Mov Disord. 1989;4(4):349-53. doi: 10.1002/mds.870040411.
6
Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy.苯海索治疗脑瘫继发性肌张力障碍患儿的前瞻性开放标签临床试验。
J Child Neurol. 2007 May;22(5):530-7. doi: 10.1177/0883073807302601.
7
Tardive dystonia: treatment with trihexyphenidyl.迟发性肌张力障碍:用苯海索治疗
J Clin Psychopharmacol. 1985 Aug;5(4):247-8. doi: 10.1097/00004714-198508000-00017.
8
[Treatment of dystonia with high-dosage trihexyphenidyl].[高剂量苯海索治疗肌张力障碍]
Rinsho Shinkeigaku. 1984 Aug;24(8):769-77.
9
[A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent].[一例阿莫沙平所致迟发性肌张力障碍经低剂量抗胆碱能药物成功治疗的病例]
Rinsho Shinkeigaku. 2000 Apr;40(4):367-71.
10
Involvement of respiratory muscles in adult-onset dystonia: a clinical and electrophysiological study.成人起病性肌张力障碍中呼吸肌的受累情况:一项临床与电生理研究。
Mov Disord. 1995 Nov;10(6):708-13. doi: 10.1002/mds.870100603.

引用本文的文献

1
Acute Movement Disorders in Childhood.儿童急性运动障碍
J Clin Med. 2021 Jun 17;10(12):2671. doi: 10.3390/jcm10122671.
2
Famotidine, a Histamine H Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study.法莫替丁,一种组胺H受体拮抗剂,不能减轻帕金森病中左旋多巴诱发的异动症:一项概念验证研究。
Mov Disord Clin Pract. 2014 Jun 26;1(3):219-224. doi: 10.1002/mdc3.12061. eCollection 2014 Sep.
3
Holoprosencephaly-Associated Hyperkinesia.全前脑畸形相关的运动亢进
Mov Disord Clin Pract. 2015 May 9;2(3):310-312. doi: 10.1002/mdc3.12176. eCollection 2015 Sep.
4
Development of Hyperkinesias after Long-term Pallidal Stimulation for Idiopathic Segmental Dystonia.特发性节段性肌张力障碍长期苍白球刺激后运动亢进的发生
Tremor Other Hyperkinet Mov (N Y). 2017 Sep 19;7:480. doi: 10.7916/D8V416KN. eCollection 2017.
5
Drug-induced movement disorders.药物性运动障碍
Drug Saf. 1997 Mar;16(3):180-204. doi: 10.2165/00002018-199716030-00004.